Phase II trial of topotecan in advanced breast cancer. A cancer and leukemia group B study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 22, Issue 3, 1999, Pages 218-222

  Levine, Ellis G ^a   Cirrincione, Constance T ^b   Szatrowski, Ted P ^c   Canellos, George ^d   Norton, Larry ^e   Craig Henderson, I ^f  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b CALGB Statistical Center   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast neoplasms; Clinical trials; Phase II; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE INHIBITOR; TOPOTECAN;

ADULT; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG INDUCED DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME; VOMITING;

EID: 0033502974     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199906000-00002     Document Type: Article

References (23)

1. Rowinski E, Grochow L, Hendricks C, et al. Phase I and pharmacologic study of topotecan (SK&F 104864,): a novel topoisomerase I inhibitor [Abstract 240]. Proc Am Soc Clin Oncol 1991;10:93.
2. Burds HA III, Hanauske AR, Johnson RK, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony forming units in vitro. J Natl Cancer Inst 1992;84:1816-20.
3. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev 1994;20:73-96.
4. Sirott MN, Saltz L, Young C, et al. Phase I and clinical pharmacologic study of intravenous topotecan (T) [Abstract 284]. Proc Am Soc Clin Oncol 1991;10:104.
5. Recondo G, Abbruzzese J, Newman B, et al. A phase I trial of topotecan administered by a 24-hour infusion [Abstract 1229]. Proc Am Assoc Cancer Res 1991;32:206.
6. Wall J, Burris H, Rodriguez G, et al. Phase I trial of topotecan (SK&F 104864) in patients with refractory solid tumors [Abstract 261]. Proc Am Soc Clin Oncol 1991;10:98.
7. Grochow LB, Rowinsky EK, Johnson R, et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 1992;20:706-13.
8. Saltz L, Sirott M, Young C, et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 1993;85:1499-507.
9. van Warmerdam LJC, Verweij J, Schellens JHM, et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 1995;35: 237-45.
10. Rowinsky EK, Grochow LB, Hendricks CB, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992;10:647-56.
11. Verweij J, Lund B, Beijnen J, et al. Phase I and pharmacokinetics study of topotecan: a new topoisomerase I inhibitor. Ann Oncol 1993;4:673-678.
12. Dennis MJ, Beijnen JH, Grochow LB, et al. An overview of the clinical pharmacology of topotecan. Semin Oncol 1997;24(suppl 5):12-8.
13. Chang AY, Garrow G, Boros L, et al. Clinical and laboratory studies of topotecan in breast cancer [Abstract 118]. Proc Am Soc Clin Oncol 1995;14:105.
14. Bonneterre J, Pion JM, Adenis A, et al. A phase II study of a new camptothecin analogue CPT-11 in previously treated advanced breast cancer patients [Abstract 179]. Proc Am Soc Clin Oncol 1993;12:94.
15. Burris HA, Rothenberg ML, Kuhn JG, et al. Clinical trials with the topoisomerase I inhibitors. Semin Oncol 1992;19:663-9.
16. Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethyl-10-(4-(1-piperidino)-1-piperidino)carbonyloxy camptothecin, a novel water soluble derivative of campthothecin, against murine tumors. Cancer Res 1987;47:5944-7.
17. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993;85:271-91.
18. Abrams JS, Vena DA, Baltz J, et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute treatment referral center trial. J Clin Oncol 1995;13:2056-65.
19. Seidman AD, Reichman BS, Crown JPA, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995;13:1152-9.
20. Ravdin PM, Bums HA III, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879-85.
21. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886-94.
22. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995;13: 2731-6.
23. Degardin M, Bonneterre J, Hecquet B, et al. Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994;5:423-6.